Suggested remit: To appraise the clinical and cost effectiveness of trastuzumab deruxtecan within its marketing authorisation for HER2-positive unresectable or metastatic breast cancer after trastuzumab and a taxane
Status In progress
Process STA 2018
ID number 3909

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
02 November 2021 - 30 November 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
22 December 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance